Mylan Begins Marketing BenzaClin Acne Generic

27 August 2009 (Last Updated August 27th, 2009 18:30)

Mylan Pharmaceuticals has begun marketing the first generic version of Sanofi Aventis' BenzaClin. The preparation, the first to be approved by the US Food and Drug Administration (FDA), consists of 1% clindamycin and 5% benzoyl peroxide gel based on an agreement with licensing partner Dow

Mylan Pharmaceuticals has begun marketing the first generic version of Sanofi Aventis’ BenzaClin.

The preparation, the first to be approved by the US Food and Drug Administration (FDA), consists of 1% clindamycin and 5% benzoyl peroxide gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International.

Dow received FDA approval for its for clindamycin 1% and benzoyl peroxide 5% gel, a prescription-strength topical antibiotic used to treat acne, on 11 August.

BenzaClin had total US sales of approximately $221m for the 12 months ending 30 June.